Physician profile
Jacob Bollinger
NPI 1952944316
$1,813.52
in general payments reported to CMS, 2019-2025
18 companies · $894 in 2025
The $894 reported for 2025 was more than what 81% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $30.37 · 2023: $365 · 2024: $523 · 2025: $894.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,693 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,693.15 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $404.18 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $297.54 | 2022-2025 | Repatha, Otezla, Otezla |
| Novo Nordisk INC | $228.10 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $161.78 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $115.55 | 2023-2025 | Trintellix |
| Astrazeneca Pharmaceuticals LP | $90.93 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Sumitomo Pharma America, INC. | $84.61 | 2023-2025 | Gemtesa |
| Dexcom, INC. | $83.36 | 2023-2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $77.13 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $47.00 | 2023-2024 | Verquvo, Capvaxive, Gardasil |
| E.R. Squibb & Sons, L.L.C. | $44.14 | 2023-2025 | Eliquis, Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.85 | 2022-2024 | Tradjenta, Jardiance |
| Abbvie INC. | $29.48 | 2024-2025 | |
| Kowa Pharmaceuticals America, INC. | $29.19 | 2023-2025 | Zoryve, Livalo, Seglentis |
| Boston Scientific Corporation | $27.33 | 2025 | Ams 700 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $24.23 | 2023 | Rexulti |
| Glaxosmithkline, LLC. | $17.43 | 2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Lexicon Pharmaceuticals, INC. | $13.69 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Bollinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.